Mark E. Schurdak

Mark E. Schurdak

Auto-generated profile, based on publicly available information

Mark E. Schurdak

Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA, USA

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2014 in Scientific Reports
Verified
Journal Article
Open access
KWKatsuhiko Warita
Katsuhiko Warita
TWTomoko Warita
Tomoko Warita
CBColin H. Beckwitt
Colin H. Beckwitt
MSMark E. Schurdak
Mark E. Schurdak
AVAlexei Vazquez
Alexei Vazquez
ZOZoltan N. Oltvai
Zoltan N. Oltvai
The cholesterol reducing drugs, statins, exhibit anti-tumor effects against cancer stem cells and various cancer cell lines, exert potent additivity or synergy with existing chemotherapeutics in animal models of cancer and may reduce cancer incidence and cancer related mortality in humans. However, not all tumor cell lines are sensitive to statins, and clinical trials have demonstrated mixed outcomes regarding statins as anticancer agents. Here, we show that statin-induced reduction in intracellular cholesterol levels correlate with the growth inhibition of cancer cell lines upon statin treatment. Moreover, statin sensitivity segregates with abundant cytosolic vimentin expression and absent cell surface E-cadherin expression, a pattern characteristic of mesenchymal-like cells. Exogenous expression of cell surface E-cadherin converts statin- sensitive cells to a partially resistant state implying that statin resistance is in part dependent on the tumor cells attaining an epithelial phenotype. As metastasizing tumor cells undergo epithelial to mesenchymal transition during the initiation of the metastatic cascade, statin therapy may represent an effective approach to targeting the cells most likely to disseminate.

1 May 2007 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SMSusan E. Morgan-Lappe
Susan E. Morgan-Lappe
LTLora A. Tucker
Lora A. Tucker
XHXiaoli Huang
Xiaoli Huang
QZQian Zhang
Qian Zhang
ASAparna V. Sarthy
Aparna V. Sarthy
SFStephen W. Fesik
Stephen W. Fesik
To identify new candidate cancer drug targets, we used RNAi as a tool to functionally evaluate genes that play a role in maintaining human tumor cell survival. We screened a small interfering RNA (siRNA) library directed against ∼3,700 individual genes to assess the ability of siRNAs to induce cell death in an in vitro cell cytotoxicity assay. We found that siRNAs specifically targeting ras-related nuclear protein (Ran), targeting protein for Xenopus kinesin-like protein 2 (TPX2), and stearoyl-CoA desaturase 1 (SCD1), significantly reduced the survival of multiple human tumor cell lines. Further target validation studies revealed that treatment with Ran and TPX2 siRNAs differentially reduced the survival of activated K-Ras–transformed cells compared with their normal isogenic counterparts in which the mutant K-Ras gene had been disrupted (DKS-8). Knockdown of Ran and TPX2 in activated mutant K-Ras cells selectively induced S-phase arrest or transient G2-M arrest phenotypes, respectively, that preceded apoptotic cell death. Given our observations that Ran and TPX2 depletion preferentially reduces the survival of activated K-Ras–transformed cells, these two proteins may serve as useful anticancer targets in tumors expressing the activated K-Ras oncogene. [Cancer Res 2007;67(9):4390–7]

2 October 2014 in Organogenesis
Verified
Journal Article
Closed access
LDLeonardo D’aIuto
Leonardo D’aIuto
YZYun Zhi
Yun Zhi
DDDhanjit Kumar Das
Dhanjit Kumar Das
MWMadeleine R Wilcox
Madeleine R Wilcox
JJJon W Johnson
Jon W Johnson
VNVishwajit L Nimgaonka
Vishwajit L Nimgaonka
Induced pluripotent stem cell (iPSC)-based technologies offer an unprecedented opportunity to perform high-throughput screening of novel drugs for neurological and neurodegenerative diseases. Such screenings require a robust and scalable method for generating large numbers of mature, differentiated neuronal cells. Currently available methods based on differentiation of embryoid bodies (EBs) or directed differentiation of adherent culture systems are either expensive or are not scalable. We developed a protocol for large-scale generation of neuronal stem cells (NSCs)/early neural progenitor cells (eNPCs) and their differentiation into neurons. Our scalable protocol allows robust and cost-effective generation of NSCs/eNPCs from iPSCs. Following culture in neurobasal medium supplemented with B27 and BDNF, NSCs/eNPCs differentiate predominantly into vesicular glutamate transporter 1 (VGLUT1) positive neurons. Targeted mass spectrometry analysis demonstrates that iPSC-derived neurons express ligand-gated channels and other synaptic proteins and whole-cell patch-clamp experiments indicate that these channels are functional. The robust and cost-effective differentiation protocol described here for large-scale generation of NSCs/eNPCs and their differentiation into neurons paves the way for automated high-throughput screening of drugs for neurological and neurodegenerative diseases.

29 May 2007 in Hepatology
Verified
Journal Article
Closed access
PDF file
TNTeresa Ng
Teresa Ng
HMHongmei Mo
Hongmei Mo
TPTami Pilot-Matias
Tami Pilot-Matias
YHYupeng He
Yupeng He
GKGennadiy Koev
Gennadiy Koev
AMAkhteruzzaman Molla
Akhteruzzaman Molla

1 March 2017 in SLAS Discovery
Verified
Journal Article
Open access
PDF file
AGAlbert Gough
Albert Gough
ASAndrew M. Stern
Andrew M. Stern
JMJohn Maier
John Maier
TLTimothy Lezon
Timothy Lezon
TSTong-Ying Shun
Tong-Ying Shun
DTD. Lansing Taylor
D. Lansing Taylor
Heterogeneity is a fundamental property of biological systems at all scales that must be addressed in a wide range of biomedical applications, including basic biomedical research, drug discovery, d... 抄録ばらつきは、基礎生物医学研究、創薬、診断及び精密医療(precision medicine)の実施など、幅広い生物医学の適用範囲において取り組まなければならないすべての評価基準における生体系の根本的特性である。細胞のばらつきをin vitro(試験管内)及び組織切片において特徴付けるための公表されたアプローチは多数ある。しかし、相対的に高いスループットのワークフローに応用できるばらつきの... 초록이질성은 기본적인 생체의학 연구, 약물 발견, 진단 및 정밀 의학의 구현을 포함하여 광범위한 생물의학 응용 분야에서 다루어져야 하는 모든 규모의 생물 시스템의 기본 특성입니다. 시험관 내 및 조직 섹션에서 세포의 이질성을 특성화하기 위한 다수의 공개된 접근법이 있습니다. 그러나 상대적으로 높은 처리량의 워크플로에 적용될 수 있는 바이러스의 이질성에... 摘要异质性是任何规模的生物系统都具备的基本特性,须在 包括基础生物医学研究、药物研发、诊断和精准施药等 广泛的生物医学应用中得到解决。现已有一些 已公布的方法可描述体外细胞和组织切片的异质性。 然而,还没有出现公认的可用于相对高通量工作流的检测和定量 异质性的方法。这一回顾和 观点强调了可获取多路复用细胞级数据的实验方法,以及 异质性的空间、时间和种群组成的标准度量 需求。其中建议采用一组三... 摘要異質性是任何規模的生物系統都具備的基本特性,須在 包括基礎生物醫學研究、藥物研發、診斷和精准施藥等 廣泛的生物醫學應用中得到解決。現已有一些 已公佈的方法可描述體外細胞和組織切片的異質性。 然而,還沒有出現公認的可用於相對高通量工作流的檢測和定量 異質性的方法。這一回顧和 觀點強調了可獲得多工細胞級資料的實驗方法,以及 異質性的空間、時間和種群組成的標準度量 需求。其中建議採用一組三個的...

1 January 1991
Verified
Book Chapter
Closed access
PDF file
DJDonald M. Jerina
Donald M. Jerina
ACAnju Chadha
Anju Chadha
ACAlbert M. Cheh
Albert M. Cheh
MSMark E. Schurdak
Mark E. Schurdak
AWAlexander W. Wood
Alexander W. Wood
JSJane M. Sayer
Jane M. Sayer